Back to results
US 9,433,618 B2Granted
Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors
AssigneeNivalis Therapeutics, Inc.
InventorsXicheng Sun, Jian Qiu, Adam Stout
Life of this patent
Estimating the term…
Abstract
The present invention is directed to novel quinoline compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.
Claims9
A method of inhibiting the activity of the enzyme S-nitrosoglutathione reductase (GSNOR) comprising the step of contacting said enzyme with a compound of formula I:
- wherein
- m is selected from the group consisting of 0, 1, 2, or 3;
- R1 is independently selected from the group consisting of chloro, fluoro, bromo, cyano, and methoxy;
- R2b and R2c are independently selected from the group consisting of hydrogen, halogen, C1-C3 alkyl, fluorinated C1-C3 alkyl, cyano, C1-C3 alkoxy, and N(CH3)2;
- X is selected from the group consisting of
- n is selected from the group consisting of 0, 1, and 2;
- R3 is independently selected from the group consisting of halogen, C1-C3 alkyl, fluorinated C1-C3 alkyl, cyano, C1-C3 alkoxy, and NR4R4′ where R4 and R4′ are independently selected from the group consisting of C1-C3 alkyl, or R4 when taken together with R4′ form a ring with 3 to 6 members;
- and
- A is selected from the group consisting of
- or a pharmaceutically acceptable salt, stereoisomer, or N-oxide thereof.
7 more elements
Dependencies are inferred from the claim text.